Indication
Relapsed Malignant Solid Neoplasm
1 clinical trial
1 product
Product
AUR107Clinical trial
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)Status: Recruiting, Estimated PCD: 2025-06-01